ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Renal Cell Carcinoma
Neoplasm Metastasis
Triple Negative Breast Cancer

Melanoma trials near Washington, DC, USA:

Neoadjuvant Darovasertib in Primary Uveal Melanoma

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma...

Enrolling
Uveal Melanoma
Procedure: Primary Local Therapy
Drug: Darovasertib

Phase 3

Ideaya Biosciences

Baltimore, Maryland, United States and 74 other locations

In this phase II advanced melanoma study, all patients will receive treatment with nivolumab/ipilimumab plus cabozantinib for a 12 week indu...

Active, not recruiting
Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Georgetown University
Georgetown University

Washington, District of Columbia, United States and 2 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Bethesda, Maryland, United States and 71 other locations

cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...

Active, not recruiting
Mucosal Melanoma
Melanoma
Drug: Phase 1b: APG-115+pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Washington, District of Columbia, United States and 20 other locations

The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...

Enrolling
Melanoma
Drug: fianlimab
Drug: cemiplimab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Fairfax, Virginia, United States and 100 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Biological: Durvalumab
Drug: Ceralasertib

Phase 2

AstraZeneca
AstraZeneca

Lutherville-Timonium, Maryland, United States and 65 other locations

and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma...

Active, not recruiting
Advanced Melanoma
Drug: Botensilimab
Drug: Balstilimab

Phase 2

Agenus
Agenus

Washington, District of Columbia, United States and 50 other locations

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Active, not recruiting
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Fairfax, Virginia, United States and 152 other locations

patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...

Active, not recruiting
Melanoma Stage IV
Melanoma Stage III
Biological: Cemiplimab
Biological: BNT111

Phase 2

BioNTech
BioNTech

Fairfax, Virginia, United States and 48 other locations

treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...

Active, not recruiting
Melanoma
Ocular Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Suthee Rapisuwon

Washington, District of Columbia, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems